Intrexon Corporation (XON) Stock: Here’s What’s Happening


Intrexon Corporation (XON) is making a move down in the market today. The stock, one that is focused in the biotech industry, is currently trading at $5.71 after a move down of -5.31% so far in today’s session. In terms of biotech companies, there are several factors that have the ability to generate declines in the market. One of the most common is news. Here are the recent headlines centered around XON:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-03-19 06:06AM Have Insiders Been Selling Intrexon Corporation (NASDAQ:XON) Shares This Year?
Sep-26-19 07:30AM David H. Witte to lead MBP Titan LLC
Sep-24-19 04:00AM Next Green Wave Achieves Operational Milestones For Intrexons Botticelli Cannabis Plantlet Production
Aug-29-19 09:01AM Teladoc Gains on Growing Acceptance for TeleHealth Services
Aug-19-19 07:30AM ActoBio Therapeutics Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients’ Tolerance of Gluten

Nonetheless, any time investors are making an investing decision, prospective investors should take a look at much more than just news, this is especially the case in the speculative biotechnology space. Here’s what’s happening with Intrexon Corporation.

How XON Has Been Trending

While a move down on a single session, like the move that we’re seeing from Intrexon Corporation might cause fear in some investors, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It’s always important to take a look at trends experienced by the stock just a single trading session. In the case of XON, below are the returns on investment that we’ve seen:

  • Past Seven Days – Throughout the last week, XON has seen a price change that amounts to -4.19%.
  • Monthly – The monthly ROI from Intrexon Corporation works out to -11.75%.
  • Past Quarter – In the last 3 months, the stock has produced a ROI that works out to -26.32%
  • Bi-Annually – Over the previous 6 months, investors have seen a change that works out to 10.02% from the company.
  • YTD – Since the open of this year XON has generated a ROI of -12.69%.
  • Annually – Lastly, in the last year, we’ve seen a change that works out to -64.56% from XON. Over this period of time, the stock has traded at a high price of -65.27% and a low price of 44.56%.

Ratios Worth Paying Attention To

Looking at various key ratios having to do with a stock can give traders a look of how dangerous and/or potentially profitable a stock pick might be. Below are some of the key ratios to look at when digging into XON.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. As the short ratio goes higher, it shows that more investors have a belief that the stock is going to tumble. In general, biotech stocks tend to have a higher short ratio. However, we also see a lot of short squeezes in the space. Nonetheless, when it comes to Intrexon Corporation, it’s short ratio comes to 31.99.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Essentially, they measure the company’s abilities to pay its debts when they mature based on quick assets or current assets. Because many biotech many companies are heavily reliant on the continuation of support from investors, these ratios can be damning. Nonetheless, some good picks in the biotechnology space do have great quick and current ratios. In terms of XON, the quick and current ratios work out to 3.20 and 3.50 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the price of shares. In this case, the book to share value ratio is 1.82.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotechnology sector, this is a very important ratio to think about. In the case of XON, the cash to share value ratio comes to 0.77.

What Analysts Think About Intrexon Corporation

Although it’s never a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their opinions when validating your own opinions when it comes to making an investment decision in the biotechnology space. Below you’ll find the most recent moves that we have seen from analysts when it comes to XON.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-01-19 Downgrade Northland Capital Outperform → Market Perform
Jul-17-18 Resumed Stifel Buy $72
Jul-16-18 Downgrade BofA/Merrill Neutral → Underperform
Nov-10-17 Reiterated Stifel Buy $57 → $39
Nov-10-17 Reiterated Stifel Buy $39 → $57

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in XON, here’s what we’re seeing:

Institutions own 75.00% of the company. Institutional interest has moved by 0.17% over the past three months. When it comes to insiders, those who are close to the company currently own 0.30% percent of XON shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What You Need To Know About Share Counts

Investors and traders tend to have a heavy interest in the amounts of shares both available and outstanding. When it comes to Intrexon Corporation, there are currently 163.18M and there is a float of 136.92M. These data mean that out of the total of 163.18M shares of XON that are out there today, 136.92M are able to trade hands in the public realm.

I also find it important to pay attention to the short percentage of the float. Think about it, if a high portion of the float is sold short, the overall opinion in the market is that the stock is going to fall hard. When it comes to XON, the percentage of the float that is currently being sold short sits at 25.42%. Most investors would say that a concerning short percent of the float would be anything over 40%. Through my work, I have seen that a short ratio over 26% is generally a play that comes with hefty risk.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.90. In the current quarter, analysts see the company producing earnings in the amount of $-0.24. Over the last 5 years, XON has generated revenue in the amount of $46.50% with earnings coming in at -22.90%. On a quarter over quarter basis, earnings have seen movement of 50.10% and revenue has seen movement of -20.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, by my very nature, I can learn by myself. Nonetheless, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at information? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here